Adjuvant intravenous immunoglobulin in elderly sepsis: a randomized controlled study of mortality, organ function, and inflammation - Takeaways - MDSpire

Adjuvant intravenous immunoglobulin in elderly sepsis: a randomized controlled study of mortality, organ function, and inflammation

  • By

  • Xiaoyun Miao

  • Jiaxin Shen

  • Jinglin Zhao

  • Rui Wang

  • Hao Wang

  • Qingchun Dai

  • June 24, 2026

  • 0 min

Share

  • 1

    The study evaluated the efficacy and safety of intravenous immunoglobulin (IVIG) as an adjunct therapy in elderly patients with sepsis.

  • 2

    120 elderly patients were randomized to receive either IVIG plus conventional therapy or conventional therapy alone, with a focus on mortality and organ function.

  • 3

    IVIG treatment was associated with a significant reduction in 28-day mortality (18.3% vs. 31.7%) and a more rapid decline in SOFA scores.

  • 4

    Patients receiving IVIG showed greater decreases in inflammatory markers CRP and PCT, along with shorter ICU stays and mechanical ventilation durations.

  • 5

    Adverse events were infrequent and comparable between the IVIG and control groups, indicating a favorable safety profile for IVIG in this population.

Original Source(s)

Adjuvant intravenous immunoglobulin in elderly sepsis: a randomized controlled study of mortality, organ function, and inflammation

  • by Xiaoyun Miao, Jiaxin Shen, Jinglin Zhao, Rui Wang, Hao Wang, Qingchun Dai

  • June 24, 2026

Related Content

From principles to practice: learning antimicrobial stewardship through the ESICM fellowship

RNA modifications shape innate immunity and cellular adaptation during bacterial respiratory infection

Gut barrier-microbiota crosstalk in sepsis: from pathogenesis to potential therapies